Edaravone (MCI-186)

Description: Edaravone (formerly known as Radicut; MCI-186; trade name: Radicava) is a novel and potent free radical scavenger that has been used clinically to reduce the neuronal damage following ischemic stroke. In May 2017, it was approved by FDA to treat patients with amyotrophic lateral sclerosis (ALS). Edaravone inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. It was approved by FDA in May 5th 2017 for the treatment of amyotrophic lateral sclerosis (ALS). Edaravone reduces apoptosis and necrosis caused by glutamate. Pretreatment of edaravone (500?uM) reverses these changes to approximately normal levels.

References: CNS Drug Rev. 2006 Spring; 12(1):9-20; Stroke. 2005 Oct; 36(10):2220-5.